Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moxifloxacin HCl 0.5% Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

NCT00312338
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
VIGAMOX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year to 13 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 2, 2026, 7:01 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

NCT04205916
View directory record Official record
Conditions
Patient Preference
Interventions
Dexamethasone, Standard of care surgery
Drug · Other
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
22 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

NCT00464438
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
gatifloxacin, moxifloxacin 0.5% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
Up to 31 Days
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 2, 2026, 7:01 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

NCT00347828
View directory record Official record
Conditions
Eye Infection, Infection
Interventions
Moxifloxacin ophthalmic solution 0.5%, Gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Oct 2, 2026, 7:01 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 2, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional Results available

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

NCT01928693
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution
Drug
Lead sponsor
Cornea Consultants Of Nashville
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020
View directory record Official record
Conditions
Corneal Infiltrates
Interventions
Moxifloxacin/dexamethasone phosphate ophthalmic solution, Moxifloxacin ophthalmic solution 0.5%, Dexamethasone phosphate solution, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Results available

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

NCT00824070
View directory record Official record
Conditions
Cataract Extraction
Interventions
Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Dropless vs. Standard Drops Contralateral Eye Study

NCT02515045
View directory record Official record
Conditions
Cataract
Interventions
TriMoxiVanc, Moxifloxacin HCl 0.5%, Ilevro, Prednisolone acetate 1%
Drug
Lead sponsor
Carolina Eyecare Physicians, LLC
Other
Eligibility
50 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Bloomington, Minnesota • Stillwater, Minnesota • Garden City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

NCT00905762
View directory record Official record
Conditions
Healthy
Interventions
Gatifloxacin, Moxifloxacin, Besifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Steroids for Corneal Ulcers Trial

NCT00324168
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Bacterial
Interventions
Antibiotics, Topical corticosteroid, Placebo
Drug
Lead sponsor
Thomas M. Lietman
Other
Eligibility
16 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
San Francisco, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00332293
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Month and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

NCT04019574
View directory record Official record
Conditions
Healthy
Interventions
CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet, Placebo
Drug · Other
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

NCT00630019
View directory record Official record
Conditions
Cataract
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

NCT04083833
View directory record Official record
Conditions
TQT Study
Interventions
Tetrodotoxin, Placebos
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 2, 2026, 7:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

NCT06681688
View directory record Official record
Conditions
Cataract
Interventions
Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Drug
Lead sponsor
Inder Paul Singh, M.D.
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Venice, Florida • Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

NCT03258515
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD6094 200 mg, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

NCT00874887
View directory record Official record
Conditions
Anti-biotic Resistance
Interventions
moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT01455233
View directory record Official record
Conditions
Corneal Health, Cataract Surgery
Interventions
besivance, vigamox
Drug
Lead sponsor
Ophthalmology Consultants, Ltd.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103
View directory record Official record
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 2, 2026, 7:01 AM EDT